Changzhou Qianhong Biopharma Co., Ltd.

Changzhou Qianhong Biopharma Co., Ltd. has seen a notable rise in its stock today, contrasting with the modest gain of the China Shanghai Composite. While the company has shown short-term resilience, it faces longer-term challenges, including declines in net sales and profits, necessitating strategic reassessment.

Changzhou Qianhong Biopharma Co., Ltd. saw a significant intraday rise on June 29, 2026, contrasting with the broader market's modest gains. Despite recent short-term increases, the company has struggled over the past year, facing declines in net sales and profitability, while operating in the Pharmaceuticals & Biotechnology sector.

Changzhou Qianhong Biopharma Co., Ltd. saw a significant intraday increase on March 24, 2026, despite recent declines. Over the past year, the company has outperformed the Shanghai Composite index. It has reported positive financial results, including a net profit of CNY 380.07 million and a high dividend yield.

Changzhou Qianhong Biopharma Co., Ltd. saw a significant stock decline today, contrasting with broader market trends. Despite recent short-term challenges, the company has demonstrated resilience over the past year, reporting positive financial results and maintaining a commitment to shareholder value through dividends.